Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007 : the IeDEA Southern Africa collaboration

SUNScholar Research Repository

Show simple item record Cornell, Morne Technau, Karl Fairall, Lara Wood, Robin Moultrie, Harry Van Cutsem, Gilles Giddy, Janet Mohapi, Lerato Eley, Brian MacPhail, Patrick Prozesky, Hans Rabie, Helena Davies, Mary-Ann Maxwell, Nicola Boulle, Andrew 2011-03-18T14:59:22Z 2011-03-18T14:59:22Z 2009-09
dc.identifier.citation Cornell, M. et al. 2009. Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: The IeDEA Southern Africa collaboration. South African Medical Journal, 99(9):653-660.
dc.identifier.issn 2078-5135 (online)
dc.identifier.issn 0256-9574 (print)
dc.description Article
dc.description The original publication is available at
dc.description.abstract Objectives. To introduce the combined South African cohorts of the International epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration as reflecting the South African national antiretroviral treatment (ART) programme; to characterise patients accessing these services; and to describe changes in services and patients from 2003 to 2007. Design and setting. Multi-cohort study of 11 ART programmes in Gauteng, Western Cape, Free State and KwaZulu-Natal. Subjects. Adults and children (<16 years old) who initiated ART with ≥3 antiretroviral drugs before 2008. Results. Most sites were offering free treatment to adults and children in the public sector, ranging from 264 to 17 835 patients per site. Among 45 383 adults and 6 198 children combined, median age (interquartile range) was 35.0 years (29.8-41.4) and 42.5 months (14.7-82.5), respectively. Of adults, 68% were female. The median CD4 cell count was 102 cells/μl (44-164) and was lower among males than females (86, 34-150 v. 110, 50-169, p<0.001). Median CD4% among children was 12% (7-17.7). Between 2003 and 2007, enrolment increased 11-fold in adults and 3-fold in children. Median CD4 count at enrolment increased for all adults (67-111 cells/μl, p<0.001) and for those in stage IV (39-89 cells/μl, p<0.001). Among children <5 years, baseline CD4% increased over time (11.5-16.0%, p<0.001). Conclusions. IeDEA-SA provides a unique opportunity to report on the national ART programme. The study describes dramatically increased enrolment over time. Late diagnosis and ART initiation, especially of men and children, need attention. Investment in sentinel sites will ensure good individual-level data while freeing most sites to continue with simplified reporting.
dc.format.extent p. 653-660
dc.language.iso en_ZA
dc.publisher Health and Medical Publishing Group (HMPG)
dc.subject HIV infections -- Treatment -- South Africa en_ZA
dc.subject AIDS (Disease) -- Treatment -- South Africa en_ZA
dc.subject South African National Antiretroviral Treatment Programme en_ZA
dc.title Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007 : the IeDEA Southern Africa collaboration en_ZA
dc.type Article
dc.description.version Publishers’ Version
dc.rights.holder SAMJ reserves copyright of the material published
 Find Full text

Files in this item

This item appears in the following Collection(s)

Show simple item record